Why Akero Therapeutics is the Healthcare Stock Everyone’s Watching in 2025
Akero Therapeutics has become one of the top-performing healthcare stocks in 2025, defying a struggling sector. The company is advancing its flagship drug, efruxifermin (EFX), through phase 3 clinical trials to address metabolic dysfunction-associated steatohepatitis (MASH). Akero’s stock surged by 81.60%, driven
